← TagsCompany

Calytrix Bio

1 articles

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion to expand its rare blood cancer treatment pipeline. This acquisition strengthens Lilly's hematology portfolio and diversifies revenu

reuters · 2026-11-16 04:19